Trial Profile

University of Washington Alzheimer's Disease Research Center (UW ADRC) Imaging & Biomarker Core

Status: Not yet recruiting

Phase of Trial: Phase IV

Latest Information Update: 07 Nov 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Florquinitau F18 (Primary)
Indications Alzheimer's disease; Dementia; Mild cognitive impairment
Focus Diagnostic use

Most Recent Events

31 Oct 2022 Planned initiation date changed from 1 Sep 2021 to 1 Nov 2022.
23 Jun 2021 Planned initiation date changed from 1 Jul 2020 to 1 Sep 2021.
25 Jun 2020 New trial record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com